Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.

Palechor-Ceron N, Krawczyk E, Dakic A, Simic V, Yuan H, Blancato J, Wang W, Hubbard F, Zheng YL, Dan H, Strome S, Cullen K, Davidson B, Deeken JF, Choudhury S, Ahn PH, Agarwal S, Zhou X, Schlegel R, Furth PA, Pan CX, Liu X.

Cells. 2019 Oct 27;8(11). pii: E1327. doi: 10.3390/cells8111327. Review.


Association of Ancestral Genetic Admixture and Excess Weight at Twelve Months of Age.

Hazrati S, Huddleston K, Sadat-Hossieny S, Tilman LW, Fuller A, Deeken JF, Wong WSW, Niederhuber JE, Hourigan SK.

Child Obes. 2020 Jan;16(1):59-64. doi: 10.1089/chi.2019.0055. Epub 2019 Oct 9.


EPG5 Variants with Modest Functional Impact Result in an Ameliorated and Primarily Neurological Phenotype in a 3.5-Year-Old Patient with Vici Syndrome.

Kane MS, Zhao J, Muskett J, Diplock A, Srivastava S, Hauser N, Deeken JF, Niederhuber JE, Smith WE, Vilboux T, Ebrahimi-Fakhari D.

Neuropediatrics. 2019 Aug;50(4):257-261. doi: 10.1055/s-0039-1692129. Epub 2019 Jun 21.


Endosomal trafficking defects in patient cells with KIAA1109 biallelic variants.

Kane MS, Diamonstein CJ, Hauser N, Deeken JF, Niederhuber JE, Vilboux T.

Genes Dis. 2019 Jan 7;6(1):56-67. doi: 10.1016/j.gendis.2018.12.004. eCollection 2019 Mar.


Clinical and social factors associated with excess weight in Hispanic and non-Hispanic White children.

Hazrati S, Khan F, Huddleston K, De La Cruz F, Deeken JF, Fuller A, Wong WSW, Niederhuber JE, Hourigan SK.

Pediatr Res. 2019 Feb;85(3):256-261. doi: 10.1038/s41390-018-0264-9. Epub 2019 Jan 10.


Germline de novo mutation clusters arise during oocyte aging in genomic regions with high double-strand-break incidence.

Goldmann JM, Seplyarskiy VB, Wong WSW, Vilboux T, Neerincx PB, Bodian DL, Solomon BD, Veltman JA, Deeken JF, Gilissen C, Niederhuber JE.

Nat Genet. 2018 Apr;50(4):487-492. doi: 10.1038/s41588-018-0071-6. Epub 2018 Mar 5.


A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.


Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Deeken JF, Beumer JH, Anders NM, Wanjiku T, Rusnak M, Rudek MA.

Cancer Chemother Pharmacol. 2015 Oct;76(4):813-9. doi: 10.1007/s00280-015-2856-y. Epub 2015 Sep 2.


RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.

Cannon TL, Kokon MA, Shafqat S, Deeken JF.

Curr Treat Options Oncol. 2015 Jul;16(7):33. doi: 10.1007/s11864-015-0350-8. Review.


A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ.

Cancer. 2015 May 15;121(10):1645-53. doi: 10.1002/cncr.29224. Epub 2015 Jan 29.


Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series.

Kress MA, Sen N, Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Hwang J, Harter KW.

Head Neck. 2015 Oct;37(10):1403-9. doi: 10.1002/hed.23763. Epub 2014 Sep 25.


A phase I study of oral ixabepilone in patients with advanced solid tumors.

Deeken JF, Marshall JL, Pishvaian MJ, Hwang J, Ahlers CM, Clemens PL, Parker SM, Iacono L, LoRusso PM.

Cancer Chemother Pharmacol. 2014 May;73(5):1071-8. doi: 10.1007/s00280-014-2443-7. Epub 2014 Mar 25.


Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma.

Deeken JF, Newkirk K, Harter KW, Marshall MB, Banovac F, Johnson L, Wang H, Wang Y, Zhuang T, Jay AK, Berkowitz F, Esposito G, Kallakury B, Davidson B.

Head Neck. 2015 May;37(5):630-5. doi: 10.1002/hed.23644. Epub 2014 Apr 30.


Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.

Rudek MA, Chang CY, Steadman K, Johnson MD, Desai N, Deeken JF.

Cancer Chemother Pharmacol. 2014 Apr;73(4):729-36. doi: 10.1007/s00280-014-2399-7. Epub 2014 Feb 2.


A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF.

Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28.


Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.

Deeken JF, Shimkus B, Liem A, Hill D, Gurtler J, Berghorn E, Townes L, Lu H, Trifan O, Zhang S.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1473-83. doi: 10.1007/s00280-013-2146-5. Epub 2013 Apr 16.


A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, Lewandowski K, Subramaniam D, He AR, Cotarla I, Rahman A, Marshall JL.

Cancer Chemother Pharmacol. 2013 Mar;71(3):627-33. doi: 10.1007/s00280-012-2048-y. Epub 2012 Dec 30.


The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ.

Clin Infect Dis. 2012 Nov;55(9):1228-35. doi: 10.1093/cid/cis613. Epub 2012 Jul 9. Review.


A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD.

Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.


Supportive treatments for oncology patients: not just icing on the cake.

Deeken JF, Weiner LM.

Ann Intern Med. 2010 Sep 21;153(6):411-2. doi: 10.7326/0003-4819-153-6-201009210-00010. No abstract available.


Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.

Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL.

Clin Cancer Res. 2010 Aug 1;16(15):4038-45. doi: 10.1158/1078-0432.CCR-10-0822. Epub 2010 Jun 10.


Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.

Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27.


Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.

Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ, Hwang J, Slack RS, Noone AM, Harter KW.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1411-9. doi: 10.1016/j.ijrobp.2009.06.070. Epub 2010 Jan 7.


Cetuximab in the treatment of rheumatoid arthritis.

Sullivan T, Benjamin CG, Kempf PW, Deeken JF.

J Clin Rheumatol. 2010 Jan;16(1):32-3. doi: 10.1097/RHU.0b013e3181c8e176.


A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.

Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.

Pharmacogenomics J. 2010 Jun;10(3):191-9. doi: 10.1038/tpj.2009.57. Epub 2009 Dec 29.


Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

Sissung TM, English BC, Venzon D, Figg WD, Deeken JF.

Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154. Review.


Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE.

Mol Pharmacol. 2009 Nov;76(5):946-56. doi: 10.1124/mol.109.056192. Epub 2009 Jul 24.


Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

Deeken JF, Pantanowitz L, Dezube BJ.

Curr Opin Oncol. 2009 Sep;21(5):445-54. doi: 10.1097/CCO.0b013e32832f3e04. Review.


The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.

Polgar O, Deeken JF, Ediriwickrema LS, Tamaki A, Steinberg SM, Robey RW, Bates SE.

Mol Cell Biochem. 2009 Feb;322(1-2):63-71. doi: 10.1007/s11010-008-9940-0. Epub 2008 Nov 11.


Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

Deeken JF, Slack R, Marshall JL.

Cancer. 2008 Oct 1;113(7):1502-10. doi: 10.1002/cncr.23777. Review.


The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.

Deeken JF, Löscher W.

Clin Cancer Res. 2007 Mar 15;13(6):1663-74. Review.


Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.

Deeken JF, Figg WD, Bates SE, Sparreboom A.

Anticancer Drugs. 2007 Feb;18(2):111-26. Review.


Immunologic therapies for gastrointestinal cancers.

Levy B, Deeken JF, Holt G, Marshall JL.

Clin Colorectal Cancer. 2005 May;5(1):37-49. Review.


Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers.

Deeken JF, Taylor KL, Mangan P, Yabroff KR, Ingham JM.

J Pain Symptom Manage. 2003 Oct;26(4):922-53. Review.

Supplemental Content

Loading ...
Support Center